Nine teams representing 19 lead and co-lead investigators across Harvard Medical School and its affiliated hospitals have received a total of over $9 million to research rare cares.
With major leadership changes, grant disruptions and terminations, and a stoked distrust in science, Steven Artandi, the director of Stanford Cancer Center, worries that young investigators will feel disenchanted by the U.S. research atmosphere and take their work and study elsewhere.
